• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by VectivBio Holding AG (Amendment)

    5/26/23 4:51:57 PM ET
    $VECT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VECT alert in real time by email
    SC 13G/A 1 d506263dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    VectivBio Holding AG

    (Name of Issuer)

     

     

    Ordinary Shares, CHF 0.05 nominal value per share

    (Title of Class of Securities)

    H9060V 101

    (CUSIP Number)

    May 25, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No.: H9060V 101

     

      1.    

      Name of Reporting Person:

     

      Novo Holdings A/S

      2.  

      Check the Appropriate Box if a Member of Group (See Instructions):

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only:

     

      4.  

      Citizenship or Place of Organization:

     

      Denmark

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power:

     

      0

       6.   

      Shared Voting Power:

     

      0

       7.   

      Sole Dispositive Power:

     

      0

       8.   

      Shared Dispositive Power:

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person:

     

      0

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares:

     

      ☐

    11.  

      Percent of Class Represented By Amount In Row (9):

     

      0%

    12.  

      Type of Reporting Person:

     

      CO

    This Amendment No. 2 amends the Schedule 13G filed with the SEC on April 8, 2021, as subsequently amended by Amendment No. 1 filed on February 2, 2023 (collectively, the “Schedule”), to report and reflect that Novo Holdings A/S ceased to be a beneficial owner of more than five percent of the Issuer’s Common Stock.

    Item 1.         (a)     Name of Issuer:

    VectivBio Holding AG

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    Aeschenvorstadt 36

    4051 Basel

    Switzerland

     

    2


    Item 2.         (a)     Name of Person Filing:

    Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the “Foundation”), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S and Novozymes A/S) and is responsible for managing the Foundation’s assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.

     

      (b)

    Address or Principal Business Office or, if none, Residence:

    Tuborg Havnevej 19

    2900 Hellerup, Denmark

     

      (c)

    Citizenship or Place of Organization:

    Denmark

     

      (d)

    Title of Class of Securities:

    Common Stock

     

      (e)

    CUSIP Number:

    H9060V 101

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership:

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

       Amount beneficially owned:      0  

    (b)

       Percent of class:      0 % 

    (c)

       Number of shares as to which such person has:   
      

    (i) Sole power to vote or to direct the vote:

         0  
      

    (ii) Shared power to vote or to direct the vote:

         0
      

    (iii) Sole power to dispose or to direct the disposition of:

         0  
      

    (iv) Shared power to dispose or to direct the disposition of:

         0  

     

    3


    Item 5.

    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group:

    Not applicable.

     

    Item 10.

    Certifications:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    4


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: May 26, 2023     Novo Holdings A/S
          /s/ Barbara Fiorini Due
          By: Barbara Fiorini Due
          Its: General Counsel, Finance & Operations
    Get the next $VECT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VECT

    DatePrice TargetRatingAnalyst
    12/13/2022$18.00Buy
    Jefferies
    7/1/2022$23.00Overweight
    Piper Sandler
    More analyst ratings

    $VECT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Memo Therapeutics AG appoints Paul Carter as Chairperson

      PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

      7/8/24 7:00:00 AM ET
      $IMTX
      $IRWD
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments